See how AI medical-record review links every fact to the exact Bates page that proves it — click any citation and jump straight to the record.
See the 60-second demo →In October 2018, Judge Paul Engelmayer of the Southern District of New York issued a 156-page opinion in the Mirena IIH MDL excluding all seven plaintiff general-causation experts — covering pediatric neurology, neurosurgery, ophthalmology, biostatistics, and pharmacology. About 1,000 cases were dismissed. The Second Circuit affirmed in 2020.
The opinion is now a recurring citation in 2024–2026 mass-tort general-causation motion practice — used by defense counsel to frame the methodology-replicability inquiry that the post-2023 FRE 702 amendment has formalized at every district-court level. It is the case that explains, in unusual detail, why credentialed experts get excluded when their methodology cannot be replicated.
If you are a plaintiff attorney with a mass-tort or pharmaceutical case in 2026, the Mirena IIH MDL is the case you should treat as the upper bound of what the defense will argue against your experts.
The plaintiffs alleged that Bayer's Mirena IUS — a levonorgestrel-releasing intrauterine contraceptive — caused idiopathic intracranial hypertension (IIH), a serious neurologic condition involving elevated cerebrospinal fluid pressure. To prove general causation, the MDL leadership retained seven experts spanning multiple specialties.
Judge Engelmayer excluded all seven in a single 156-page opinion. The opinion is unusual for two reasons. First, its length — most Daubert opinions in MDL contexts are far shorter. Second, its even-handed treatment of credentials. The opinion repeatedly acknowledged that the experts were qualified, well-credentialed, and in some cases leaders in their fields. The exclusions were not about who the experts were. They were about what their methodologies looked like under scrutiny.
The opinion's central thread is methodology-replicability — whether the experts' analytical approaches were reproducible by a different expert applying the same methodology to the same data. Across the seven experts, the court found that the methodologies were not replicable. Specific defects included:
With all seven experts out, the MDL's general-causation theory had no admissible foundation. About 1,000 cases were dismissed. The Second Circuit affirmed in 2020.
The Mirena IIH MDL is referenced repeatedly in 2024–2026 motion practice because it reads as a template for how a court evaluates qualified-but-unreliable experts. The post-2023 FRE 702 amendment formalized exactly the inquiry Judge Engelmayer's opinion already conducted: not whether the methodology is reliable in principle, but whether it was reliably applied. Trial courts now have an unusually clear roadmap.
The implications for plaintiff strategy are concrete:
Methodology-replicability is the post-2023 admissibility test in mass-tort contexts. A general-causation report that another credentialed expert in the same specialty could not reproduce — given the same data and the same methodology — is not "reliably applied" within the meaning of FRE 702 as amended. The Mirena IIH opinion was ahead of the rule on this point; the rule has now caught up.
Credentials do not insulate methodology. The Mirena IIH experts were credentialed. They were also excluded. The Acetaminophen MDL repeated the pattern in 2023–2024. The Engilis Ninth Circuit decision in 2025 repeated it in a single-plaintiff context. Credentialed experts whose methodology does not survive scrutiny still get excluded. Plaintiff firms that have built their case strategy around expert pedigree need to integrate methodology rigor at the same level.
"Shared" or chained methodology is a recurring failure mode. The Mirena IIH opinion flagged it. The Acetaminophen MDL opinion explicitly called it out — Judge Cote held that one expert's reliance on another expert's prior Bradford Hill weighting was not a methodology that has been subjected to peer review. If your case has multiple general-causation experts whose conclusions converge through shared analysis, the defense will argue that one of them is reciting the other.
Biological plausibility is a useful adjunct, not a methodology. The Mirena IIH experts leaned on biological-plausibility arguments where the actual epidemiology was thin. That move does not survive 2026 motion practice. Biological plausibility is one of the nine Bradford Hill factors and contributes weight where the mechanism is well-evidenced. It is not a substitute for the other factors.
For plaintiff attorneys evaluating any new mass-tort or pharmaceutical case, the Mirena IIH MDL is the upper bound of what the defense will argue. The cases that survive Daubert at the MDL level in 2026 will be the ones whose general-causation methodology is replicable in the strict sense — pre-specified, written, dated, reproducible by an independent expert in the same field.
Four concrete steps for any case involving general-causation epidemiology:
1. Generate a methodology-replicability score before the report is filed. The score asks: if a different qualified expert in the same specialty were given the same data and the same methodology, would they reach the same conclusion? If the answer requires the original expert's specific judgment calls — selection of studies, weighting decisions, biological-plausibility leaps — the methodology is not replicable in the Mirena IIH sense. Address the gaps before the defense surfaces them.
2. Pre-specify and document every methodological step. This is the same procedural posture that the Paraquat MDL exclusion underscored. Pre-specified inclusion/exclusion criteria for the literature search. Written, dated protocols for the analytical methodology. A complete enumeration of studies considered, with documented exclusion reasons. Independent application of the methodology by each retained expert, separately.
3. Pair biological-plausibility arguments with epidemiologic evidence. Biological plausibility is useful when the underlying epidemiology supports the causal inference. It is dangerous when it is used to bridge gaps in the epidemiology. Audit the report for biological-plausibility passages that are doing analytical work the epidemiology does not support; those are the passages the defense will isolate.
4. Treat the Mirena IIH opinion as the defense's playbook. Read the opinion. Map each defect Judge Engelmayer identified to the corresponding section of your own report. For each, ask whether your expert would survive the same scrutiny. If the answer is uncertain, the gap needs to be addressed before the report is finalized.
A broader strategic point: mass-tort general-causation cases have always required heavy methodology investment. The post-2023 environment requires more. The trial-court strike rate against general-causation experts in mass-tort contexts has increased markedly since the amendment, and the Mirena IIH opinion is the framework against which that strike rate is being adjudicated. Plaintiff firms running mass-tort cases at 2018 methodology standards will not survive 2026 Daubert practice.
MedLegal AI's Daubert workup tool generates a methodology-replicability score for every retained expert in a mass-tort or pharmaceutical case. The score asks whether a different expert in the same specialty, given the same data and methodology, would reach the same conclusion. The tool flags any methodological step that depends on idiosyncratic judgment without pre-specified procedural support — the recurring defect in the Mirena IIH MDL exclusions. It also requires each retained expert to perform the analysis independently rather than relying on a shared or chained methodology, and runs a biological-plausibility audit against the underlying epidemiology to surface gaps where plausibility is doing work the data does not support. The point is to prepare smarter for Daubert challenges — to give general-causation reports a methodological posture that mirrors what the post-amendment gatekeeping order looks for. You can run a free Daubert workup on your expert here.
The Mirena IIH MDL was decided five years before the 2023 FRE 702 amendment but reads in 2026 as if it had been written for it. All seven plaintiff general-causation experts excluded; about 1,000 cases dismissed; affirmed by the Second Circuit. The opinion's methodology-replicability framework is now the operating standard the defense bar uses in every mass-tort general-causation motion. The cases that survive Daubert in 2026 will be the ones whose methodology is genuinely replicable — pre-specified, written, dated, independent across experts. Build accordingly.
Run a free Daubert workup on your expert.
MedLegal AI is software, not a law firm. We do not provide legal advice. All AI-generated outputs require independent review by a licensed attorney.
Six-pattern audit on a sample case in 90 seconds. No credit card.
Try the free Daubert workup →